

Press Release

PAT up by 11% (4th Quarter FY 2025 Consolidated Results)

Mumbai, 30th April, 2025: Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 4th quarter and year ended 31st March 2025.

Q4 FY 2025 performance highlights (compared to Q4 FY 2024):

- Revenue from operations at Rs. 1,170 cr. against Rs. 1,054 cr.; up 11%.
- EBITDA at Rs. 297 cr. against Rs. 278 cr.; up 7%; EBITDA at 25%.
- Profit after tax at Rs. 225 cr. against Rs. 203 cr.; up 11%; PAT at 19%.

FY 2025 performance highlights (compared to FY 2024):

- Revenue from operations at Rs. 4,648 cr. against Rs. 4,209 cr.; up 10%.
- EBITDA at Rs. 1,260 cr. against Rs. 1,172 cr.; up 7%; EBITDA at 27%.
- Profit after tax at Rs. 920 cr. against Rs. 816 cr.; up 13%; PAT at 20%.
- Cashflow from operations (CFO) was Rs. 1,157 cr., EBITDA to CFO conversion of 92%.
- Free cashflow (FCF) was Rs. 694 cr., FCF to PAT conversion of 75%.
- ROCE stood at a healthy level of 32% and RONW at 25%.

Shareholders pay-out:

During the fiscal year, the company distributed a total of Rs. 700 cr. (Rs. 349 cr. as dividend and Rs. 351 cr. in the form of buyback). This translates to 76% payout of the total PAT of the year.

Segment wise performance:

(Rs. cr.)

Markets	Q4		Gwth%	FY		Gwth%
	FY24	FY25		FY 2024	FY 2025	
Branded Generics						
India	₹ 326	₹ 369	13%	₹ 1,308	₹ 1,452	11%
Asia	₹ 281	₹ 303	8%	₹ 1,057	₹ 1,191	13%
Africa	₹ 113	₹ 133	17%	₹ 585	₹ 750	28%
Sub-Total	₹ 720	₹ 805	12%	₹ 2,949	₹ 3,394	15%
US Generic	₹ 261	₹ 325	25%	₹ 964	₹ 1,047	9%
Africa Institution	₹ 61	₹ 28	-53%	₹ 249	₹ 147	-41%
Total	₹ 1,042	₹ 1,158	11%	₹ 4,162	₹ 4,588	10%

As per **IQVIA MAT March 2025**, our India branded generic performance exceeded IPM growth, which came mainly from **Volumes** where Ajanta was **1.8 times higher** to IPM.

Therapy	Growth %	
	IPM	Ajanta
Cardiology	12%	11%
Ophthalmology	5%	6%
Dermatology	10%	14%
Pain Management	8%	11%
Overall	8%	11%

ANDA status as at the end of FY 2025 is as below:

Particulars	FY 2025
Filed	6
Approval received	6
Launched	5
Total ANDA's commercialized	47
Awaiting approval with US FDA	22
Tentative approval	2

R&D expense:

(Rs. cr.)

Particulars	FY 2024	FY 2025	% to RO
Q4	₹ 50	₹ 63	5%
FY	₹ 208	₹ 224	5%

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 30+ countries. Many of company's products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa.

Company's state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India.

For the Last 3 financial years, company has posted healthy revenue CAGR of 11% and even stronger PAT CAGR of 25%.

Earnings Conference Call

The Company will host an Earnings Conference Call at 1630 hrs. IST (1900 hrs. SST/HKT, 1200 hrs. BST, 0700 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.

Dial-in Information

Date and Time	April 30, 2025 at 1630 – 1730 hrs IST 1900 – 2000 hrs SST/HKT 1200 – 1300 hrs BST 0700 – 0800 hrs US ET
Dial-in Numbers	
Diamond pass link for faster access	Click here to register
Universal Access	Primary Access: (+91 22 6280 1542) (+91 22 7115 8372)
International Toll Free	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

For convenience and faster connectivity to the conference, kindly follow the below steps:

1. Register through the Diamond pass link.
2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.
3. Dial the 'conference Dial-in number' you will receive on your email.
4. On system prompt dial the PASSCODE followed by # key.
5. On system prompt enter the PIN followed by # key.
6. If the line gets disconnected, you need to dial the 'conference dial-in number' again and follow the necessary steps.

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

For more details visit www.ajantapharma.com

For regular updates follow us on x.com – <https://x.com/AjantaPharmaLtd>

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 6060 9706 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 6060 9721 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Safe Harbour Statement